LUC00135I2 - - Google Patents

Download PDF

Info

Publication number
LUC00135I2
LUC00135I2 LU00135C LUC00135C LUC00135I2 LU C00135 I2 LUC00135 I2 LU C00135I2 LU 00135 C LU00135 C LU 00135C LU C00135 C LUC00135 C LU C00135C LU C00135 I2 LUC00135 I2 LU C00135I2
Authority
LU
Luxembourg
Application number
LU00135C
Other languages
French (fr)
Original Assignee
Jazz Pharmaceuticals Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00135(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Res Llc filed Critical Jazz Pharmaceuticals Res Llc
Publication of LUC00135I1 publication Critical patent/LUC00135I1/fr
Publication of LUC00135I2 publication Critical patent/LUC00135I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LU00135C 2011-10-21 2019-10-24 LUC00135I2 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550047P 2011-10-21 2011-10-21
PCT/US2012/060293 WO2013059133A1 (en) 2011-10-21 2012-10-15 Lyophilized liposomes

Publications (2)

Publication Number Publication Date
LUC00135I1 LUC00135I1 (enExample) 2019-10-25
LUC00135I2 true LUC00135I2 (enExample) 2021-02-12

Family

ID=48141268

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00135C LUC00135I2 (enExample) 2011-10-21 2019-10-24

Country Status (22)

Country Link
US (5) US10028912B2 (enExample)
EP (2) EP2768484B1 (enExample)
JP (7) JP6133308B2 (enExample)
KR (5) KR102284689B1 (enExample)
CN (2) CN104114156A (enExample)
AU (1) AU2012326370C9 (enExample)
BR (1) BR112014009305B1 (enExample)
CA (1) CA2852777C (enExample)
DK (1) DK2768484T3 (enExample)
ES (1) ES2750368T3 (enExample)
FR (1) FR19C1063I2 (enExample)
HR (1) HRP20191683T1 (enExample)
HU (2) HUE045978T2 (enExample)
IL (1) IL232161B (enExample)
LU (1) LUC00135I2 (enExample)
NL (1) NL301016I2 (enExample)
NO (1) NO2019041I1 (enExample)
PL (1) PL2768484T3 (enExample)
PT (1) PT2768484T (enExample)
RU (1) RU2648753C2 (enExample)
SI (1) SI2768484T1 (enExample)
WO (1) WO2013059133A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2768484T (pt) * 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
DK3033102T4 (da) 2013-08-13 2024-02-26 Univ Northwestern Peptidkonjugerede partikler
WO2016033384A1 (en) 2014-08-28 2016-03-03 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
KR20180016347A (ko) * 2015-04-13 2018-02-14 파운테인 테크놀로지스 인터내셔널, 엘엘씨 초-소형 지질 구조체의 생산을 위한 단일-단계 방법
CN113679689B (zh) 2015-07-22 2023-09-01 日东电工株式会社 用于纳米粒冷冻干燥物形式的组合物及方法
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
DK3419572T3 (da) 2016-02-26 2026-06-29 Massachusetts Gen Hospital Systemer og fremgangsmåder til fremstilling og administrering af medicinsk isopslæmning
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20200230057A1 (en) * 2017-07-10 2020-07-23 Immunovaccine Technologies Inc. Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof
US20240252522A1 (en) 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
BR112021026480A2 (pt) * 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
US20220273569A1 (en) * 2019-07-24 2022-09-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN115252563B (zh) * 2022-06-24 2024-07-12 石药集团中奇制药技术(石家庄)有限公司 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法
CN116003493B (zh) * 2022-12-16 2025-02-28 常州金远药业制造有限公司 一种二价铜离子及阿糖胞苷的回收方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
EP0208764A4 (en) 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4915951A (en) 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
DE68916439T2 (de) * 1988-10-05 1994-10-20 Vestar Inc Verfahren zur herstellung von liposomen mit verbesserter stabilität während des trocknens.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
DE69720979T2 (de) * 1996-02-19 2004-02-26 Amersham Health As Thermostabilisiertes kontrastmittel
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
WO2001005372A2 (en) 1999-07-16 2001-01-25 Alza Corporation A liposome composition having resistance to freeze/thaw damage
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1432403B1 (en) 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
DE60222580T2 (de) 2001-11-13 2008-06-12 Celator Pharmaceuticals, Inc. Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
EP1608337A2 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Combination compositions of camptothecins and fluoropyrimidines
JP4972545B2 (ja) 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク. アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
US7893338B2 (en) * 2004-07-15 2011-02-22 Creative Technology Ltd Method of composing music on a handheld device
CA2584583A1 (en) * 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
AU2005304914B2 (en) * 2004-11-05 2012-02-16 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
EP1817005A1 (en) 2004-11-18 2007-08-15 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1951239A2 (en) 2005-10-25 2008-08-06 Celator Pharmaceuticals, Inc. Fixed ratio drug combination treatments for solid tumors
US20090148506A1 (en) 2005-12-22 2009-06-11 Awa Dicko Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof
PT2120568T (pt) * 2007-02-16 2017-12-04 Celator Pharmaceuticals Inc Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
WO2009097011A1 (en) 2007-08-17 2009-08-06 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
CN101878024B (zh) 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送系统
WO2010043050A1 (en) 2008-10-16 2010-04-22 Celator Pharmaceuticals Corporation Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
PT2508170E (pt) 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
WO2011092708A2 (en) * 2010-02-01 2011-08-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
PT2768484T (pt) * 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados

Also Published As

Publication number Publication date
JP2017160211A (ja) 2017-09-14
HUS1900047I1 (hu) 2019-11-28
HK1201039A1 (en) 2015-08-21
JP2020007367A (ja) 2020-01-16
SI2768484T1 (sl) 2019-12-31
JP6359717B2 (ja) 2018-07-18
NL301016I1 (nl) 2019-10-30
AU2012326370A1 (en) 2014-06-05
RU2018107407A3 (enExample) 2021-05-04
HRP20191683T1 (hr) 2019-12-13
DK2768484T3 (da) 2019-10-07
KR102113753B1 (ko) 2020-05-21
CA2852777C (en) 2020-10-27
EP2768484A4 (en) 2015-04-22
LUC00135I1 (enExample) 2019-10-25
FR19C1063I1 (fr) 2019-11-22
US20180161273A1 (en) 2018-06-14
NO2019041I1 (no) 2019-11-25
RU2018107407A (ru) 2019-02-25
JP6592556B2 (ja) 2019-10-16
KR20200057104A (ko) 2020-05-25
JP2026102777A (ja) 2026-06-23
KR20140092323A (ko) 2014-07-23
KR20220141906A (ko) 2022-10-20
AU2012326370A2 (en) 2014-06-12
IL232161B (en) 2019-07-31
JP7476161B2 (ja) 2024-04-30
US20210169803A1 (en) 2021-06-10
AU2012326370B2 (en) 2017-06-01
KR20190111139A (ko) 2019-10-01
IL232161A0 (en) 2014-05-28
HUE045978T2 (hu) 2020-01-28
CN108853031A (zh) 2018-11-23
AU2012326370C9 (en) 2023-05-18
FR19C1063I2 (fr) 2020-10-30
PL2768484T3 (pl) 2019-12-31
JP2022033892A (ja) 2022-03-02
NL301016I2 (nl) 2020-04-16
EP2768484A1 (en) 2014-08-27
JP2014532623A (ja) 2014-12-08
KR102024836B1 (ko) 2019-09-24
AU2012326370C1 (en) 2023-03-30
US20230172855A1 (en) 2023-06-08
PT2768484T (pt) 2019-10-28
KR20210095746A (ko) 2021-08-02
US20140255475A1 (en) 2014-09-11
JP6133308B2 (ja) 2017-05-24
US10166184B2 (en) 2019-01-01
CN104114156A (zh) 2014-10-22
KR102452305B1 (ko) 2022-10-07
CA2852777A1 (en) 2013-04-25
ES2750368T3 (es) 2020-03-25
BR112014009305A2 (pt) 2017-04-11
EP2768484B1 (en) 2019-07-24
RU2014120475A (ru) 2015-11-27
US10028912B2 (en) 2018-07-24
BR112014009305B1 (pt) 2023-01-24
WO2013059133A1 (en) 2013-04-25
EP3572071A1 (en) 2019-11-27
US20190070112A1 (en) 2019-03-07
JP2024045183A (ja) 2024-04-02
US10835492B2 (en) 2020-11-17
RU2648753C2 (ru) 2018-03-28
JP2018150342A (ja) 2018-09-27
KR102284689B1 (ko) 2021-08-02

Similar Documents

Publication Publication Date Title
BR112013022641A2 (enExample)
BR112013031251A2 (enExample)
BR112013027245A2 (enExample)
BR112013024383A2 (enExample)
BR112013026905A2 (enExample)
BR112013023185A2 (enExample)
BR112013022995A2 (enExample)
BR112013027830A2 (enExample)
AP3853A (enExample)
BR112013023927A2 (enExample)
BR112013027452A2 (enExample)
BR112013024365A2 (enExample)
BR112013028733A2 (enExample)
AP2016009466A0 (enExample)
BR112013031556A2 (enExample)
BR112013032368A2 (enExample)
BR112013018949A2 (enExample)
BR112013032377A2 (enExample)
BR112013027761A2 (enExample)
BR112013021637A2 (enExample)
BR112013025487A2 (enExample)
BR112013023266A2 (enExample)
BR112013030734A2 (enExample)
BR112013027871A2 (enExample)
BR112013027657A2 (enExample)